Wells Fargo & Company Eloxx Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $7.2 $0 - $21	-3 Reduced 0.01%	46,703 $8,000
Q2 2022 Aug 12, 2022	BUY	$0.24 - $0.58 $8 - $19	34 Added 0.07%	46,706 $13,000
Q1 2022 May 16, 2022	BUY	$0.4 - $0.72 $0 - $1	2 Added 0.0%	46,672 $26,000
Q4 2021 Feb 14, 2022	BUY	$0.62 - $1.61 $15,686 - $40,733	25,300 Added 118.39%	46,670 $33,000
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.0 $103 - $170	-85 Reduced 0.4%	21,370 $36,000
Q2 2021 Aug 16, 2021	BUY	$1.35 - $3.36 $11,281 - $28,079	8,357 Added 63.8%	21,455 $43,000
Q1 2021 May 13, 2021	SELL	$3.02 - $4.54 $74,642 - $112,210	-24,716 Reduced 65.36%	13,098 $44,000
Q4 2020 Feb 09, 2021	BUY	$2.42 - $4.48 $21,755 - $40,275	8,990 Added 31.19%	37,814 $151,000
Q3 2020 Nov 05, 2020	SELL	$2.53 - $3.4 $18,074 - $24,289	-7,144 Reduced 19.86%	28,824 $75,000
Q2 2020 Aug 13, 2020	BUY	$1.56 - $3.65 $20,256 - $47,395	12,985 Added 56.5%	35,968 $109,000
Q1 2020 May 14, 2020	BUY	$1.96 - $7.96 $45,046 - $182,944	22,983 New	22,983 $45,000

Ticker ELOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,656,200
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.